Clinical Trials – Surufatinib for Neuroendocrine Cancer

Clinical Trials – Surufatinib for Neuroendocrine Cancer

Clinical Trials, Technical NETs
I first heard about this drug at ENETS Barcelona 2017 and then again in 2018.  It's now starting to be discussed in USA including at the 2019 ASCO conference. It was known then as Sulfatinib but for reasons unclear to me it was changed later to Surufatinib. It's a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity (TKI) associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells.  Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies.  Surufatinib, manufactured by Hutchinson China MediTech Ltd (Chi-Med), is in proof-of-concept clinical trials in the USA and…
Read More
Cancer kills but so can fake cures

Cancer kills but so can fake cures

Awareness, Living with Neuroendocrine Cancer, Patient Advocacy
No matter where you look on social media, there are millions of sites claiming that 'this' and 'that' can cure cancer.  If you analyse some of the things that can apparently 'cure' cancer, you will normally find that behind these fantasies, there is someone selling something, a book, a video, a product. I was also interested to read a number of articles about various aspects of this modern phenomenon.  Firstly in the magazine Wired, a major media company was forced to take down some cancer therapy videos after someone pointed out they were not scientifically factual.  Not just patients who get fooled by these claims then? Much of the misinformation arrives via Facebook, and YouTube, two of the most commonly used social media tools. This article suggests a shockingly large…
Read More
Pancreatic Neuroendocrine Tumours – surgical decisions and new research on molecular sub-types

Pancreatic Neuroendocrine Tumours – surgical decisions and new research on molecular sub-types

Research, Technical NETs
I offer you two subjects in one article but they are overlapping and very related. The piece of research in the 2nd half of the article is very exciting - did you know researchers have found there are two main sub-types of pNETs, one less likely to recur and metastasise than the other? This will hopefully lead to similar research in other types of Neuroendocrine Neoplasm. Background  I've written before about pancreatic NETs (pNETs), much of which has been on the awareness side of my advocacy work, particularly emphasising the differences with core Pancreatic Cancer (adenocarcinoma). Pancreatic NETs are quite difficult to diagnose and treat, some of that difficulty is due to the location of the pancreas and accessibility for surgeons and radiographers. It's not helped by the fact that…
Read More